ClinicalTrials.gg
RecruitingNCT07945158MINORITYUpdated Nov 18, 2026

MRS Imaging Evaluation for Acute Minor Stroke

An observational study in Acute Ischemic Stroke, sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Observational

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 753 studies in Ischemic Stroke with a site in China — 380 open to participants now, 399 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
134th of 188
200 · median 625
Started
2024
with 102 others
Observational
188 of 753
108 open now
Primary completion
2028-12
later than 328 of 398 live
Registered
737th of 753
by date

Among the 753 studies in Ischemic Stroke with a site in China, this one is the 134th largest by planned enrollment of the 188 observational ones that give a count, is one of 103 that started in 2024, is one of 188 observational ones, reaches primary completion later than 328 of the 398 other live ones, and was the 737th registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

380 of the 753 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

375 more — sign in →

All 380 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This prospective observational cohort study aims to investigate the association between magnetic resonance spectroscopy (MRS) parameters and early neurological deterioration (END) in patients with large vessel occluded acute ischemic stroke. Eligible patients will undergo MRS examination during the acute phase of stroke after entry into hospital, and relevant clinical, imaging, and laboratory data will be prospectively collected. Participants will then be followed to determine the occurrence of END and prognosis during the predefined observation period. The study will evaluate whether MRS-derived metabolic parameters are associated with the risk of END and explore their potential predictive value for early neurological deterioration after acute ischemic stroke.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • Early neurological deterioration
  • Magnetic resonance spectroscopy
  • Metabolic imaging
  • Mechanical thrombectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

LVO-AIS(Large vessel occluded acute ischemic stroke) within 24 hours of onset (NIHSS\< 6 points)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥ 18;
  2. Clinically diagnosed as acute ischemic stroke
  3. Baseline NIHSS score \<6;
  4. From the onset of symptoms or the last normal to enrollment within 24 hours;
  5. CTA or MRA confirms occlusion of major anterior circulation vessels (including the intracranial segment of the internal carotid artery, M1 segment and M2 segment of the middle cerebral artery with or without the extracranial segment of the internal carotid artery), and clinically determined to be responsible vessels;
  6. Patients or legal representatives are willing to comply with program requirements and data collection procedures, understand and sign forms.

Exclusion criteria

Exclusion Criteria:

  1. Pre-onset mRS ≥ 1 point;
  2. A clear history of cerebral infarction, cerebral hemorrhage, brain tumors, or other diseases affecting brain metabolism;
  3. Intolerable or uncooperative with MRI examination;
  4. Severe heart, liver, kidney dysfunction or other severe late-stage systemic diseases;
  5. Pregnancy or breastfeeding;
  6. less than 3 months;
  7. Other circumstances deemed unsuitable for this study or that may pose significant risks to patients (such as inability to understand and/or comply with study procedures and/or follow-up due to mental illness, cognitive or emotional disorders).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • Diagnostic testMagnetic Resonance Spectroscopy Imaging (MRSI)

    Magnetic resonance spectroscopy performed during the acute phase of ischemic stroke to assess cerebral metabolic characteristics.

06

What researchers measure

Primary outcomes

  1. Number of participants with early neurologic deterioration

    Early neurologic deterioration due to ischemia within 3 days after enrollment (an increase of ≥4 points compared to baseline NIHSS, excluding non-ischemic causes such as hemorrhage and epilepsy)

    Time frame: within 3 days after enrollment

Secondary outcomes

  1. Modified rankin scale

    The modified Rankin Scale (mRS) is a 7-point global disability scale with scores ranging from 0 (no symptoms) to 6 (death); higher scores indicate a worse functional outcome. The mRS will be assessed at 3 months and categorized as good functional outcome (modified Rankin Scale score 0-2; range 0-6, higher scores indicate worse outcome) versus poor functional outcome (modified Rankin Scale score 3-6; range 0-6, higher scores indicate worse outcome).

    Time frame: 3-month after enrollment

Other outcomes

  1. Mini-Mental state examination for cognitive evaluation

    The Mini-Mental State Examination (MMSE) is a brief, 30-point cognitive screening instrument that assesses orientation, registration, attention and calculation, recall, language, and visuospatial/constructional ability. Scores range from 0 to 30, and higher scores indicate better cognitive function (lower scores indicate greater cognitive impairment). Cutoffs vary by version and educational level; commonly, a score of ≤23 or ≤24 suggests cognitive impairment, and education-adjusted thresholds may be used.

    Time frame: 3 month after enrollment

  2. Dynamic changes in relative N-acetylaspartate over time

    Relative N-acetylaspartate change dynamically over time and space from the acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).

    Time frame: Acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).

  3. Montreal cognitive assessment for cognitive evaluation

    The Montreal Cognitive Assessment (MoCA) is a brief cognitive screening instrument that assesses executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. Scores range from 0 to 30, and higher scores indicate better cognitive function (lower scores indicate greater cognitive impairment). A commonly used cutoff is \<26 for detecting cognitive impairment, though education- and population-specific thresholds may be more appropriate; the original version adds 1 point for ≤12 years of education.

    Time frame: 3 month after enrollment

  4. Dynamic changes in relative lactate over time

    Relative lactate change dynamically over time and space from the acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).

    Time frame: Acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).

  5. Dynamic changes in relative choline over time

    Relative choline change dynamically over time and space from the acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).

    Time frame: Acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).

  6. Changes in lactate/N-acetylaspartate over time

    Lactate/N-acetylaspartate change dynamically over time and space from the acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).

    Time frame: Acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).

07

Study locations

1 of 1 sites recruiting
  • Clinical Research Center of Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
08

References and documents

Publications

  • Li Y, Wang T, Zhang T, Lin Z, Li Y, Guo R, Zhao Y, Meng Z, Liu J, Yu X, Liang ZP, Nachev P. Fast high-resolution metabolic imaging of acute stroke with 3D magnetic resonance spectroscopy. Brain. 2020 Dec 5;143(11):3225-3233. doi: 10.1093/brain/awaa264. PubMed 33141145 ↗
  • Dani KA, Warach S. Metabolic imaging of ischemic stroke: the present and future. AJNR Am J Neuroradiol. 2014 Jun;35(6 Suppl):S37-43. doi: 10.3174/ajnr.A3789. Epub 2014 Apr 10. PubMed 24722308 ↗
  • Seners P, Ben Hassen W, Lapergue B, Arquizan C, Heldner MR, Henon H, Perrin C, Strambo D, Cottier JP, Sablot D, Girard Buttaz I, Tamazyan R, Preterre C, Agius P, Laksiri N, Mechtouff L, Bejot Y, Duong DL, Mounier-Vehier F, Mione G, Rosso C, Lucas L, Papassin J, Aignatoaie A, Triquenot A, Carrera E, Niclot P, Obadia A, Lyoubi A, Garnier P, Crainic N, Wolff V, Tracol C, Philippeau F, Lamy C, Soize S, Baron JC, Turc G; MINOR-STROKE Collaborators. Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone. JAMA Neurol. 2021 Mar 1;78(3):321-328. doi: 10.1001/jamaneurol.2020.4557. PubMed 33427887 ↗
  • Gwak DS, Kwon JA, Shim DH, Kim YW, Hwang YH. Perfusion and Diffusion Variables Predict Early Neurological Deterioration in Minor Stroke and Large Vessel Occlusion. J Stroke. 2021 Jan;23(1):61-68. doi: 10.5853/jos.2020.01466. Epub 2021 Jan 31. PubMed 33600703 ↗
  • Safouris A, Palaiodimou L, Nardai S, Kargiotis O, Magoufis G, Psychogios K, Matusevicius M, Feil K, Ahmed N, Kellert L, Spiliopoulos S, Brountzos E, Szikora I, Sarraj A, Goyal N, Aguiar de Sousa D, Strbian D, Caso V, Alexandrov AV, Tsivgoulis G. Medical Management Versus Endovascular Treatment for Large-Vessel Occlusion Anterior Circulation Stroke With Low NIHSS. Stroke. 2023 Sep;54(9):2265-2275. doi: 10.1161/STROKEAHA.123.043937. Epub 2023 Aug 1. PubMed 37526011 ↗
  • Xue R, Zhong W, Zhou Y, He Y, Yan S, Chen Z, Wang J, Gong X, Lou M. Endovascular Treatment for Minor Acute Ischemic Strokes With Large Vessel Occlusion. J Am Heart Assoc. 2022 Dec 20;11(24):e027326. doi: 10.1161/JAHA.122.027326. Epub 2022 Dec 19. PubMed 36533622 ↗
  • Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, Chapman S, Czap AL, Dumitrascu OM, Ishida K, Jadhav AP, Johnson B, Johnston KC, Khatri P, Kimberly WT, Lee VH, Leslie-Mazwi TM, Mac Grory B, Madsen TE, Menon B, Mistry EA, Park S, Parker S, Perez de la Ossa N, Reeves M, Saiz T, Scott PA, Schwartzberg D, Sheth SA, Sporns PB, Times S, Tjoumakaris S, Wolfe SQ, Yaghi S; Peer Review Committee. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2026 Aug;57(8):e316-e436. doi: 10.1161/STR.0000000000000513. Epub 2026 Jan 26. PubMed 41582814 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2028, 52 months after the start.

Of 400 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 52 months is close to that.

Counting every sponsor, half of 442 studies reached it within 54 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Nov 18, 2026
StartActual
Aug 3, 2024
Primary completionEst.
Dec 30, 2028
CompletionEst.
Mar 30, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945158
Lead sponsor
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Responsible party
Yueqi Zhu (Director of the Department of Interventional Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Aug 3, 2024
Primary completion
Dec 30, 2028 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Jiangshan Deng, MD
Contact
johnson120@126.com
+86 021 24058404

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion